<SEC-DOCUMENT>0001019687-12-001598.txt : 20120503
<SEC-HEADER>0001019687-12-001598.hdr.sgml : 20120503
<ACCEPTANCE-DATETIME>20120503093532
ACCESSION NUMBER:		0001019687-12-001598
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120503
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120503
DATE AS OF CHANGE:		20120503

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AETHLON MEDICAL INC
		CENTRAL INDEX KEY:			0000882291
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				133632859
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21846
		FILM NUMBER:		12807737

	BUSINESS ADDRESS:	
		STREET 1:		8910 UNIVERSITY CENTER LANE, SUITE 660
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122
		BUSINESS PHONE:		858-459-7800

	MAIL ADDRESS:	
		STREET 1:		8910 UNIVERSITY CENTER LANE, SUITE 660
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BISHOP EQUITIES INC
		DATE OF NAME CHANGE:	19930602
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aethlon_8k-050311.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html>
<head>
    <title>aethlon_8k-050311.htm</title>
    <!--Licensed to: Publicease, Inc.-->
    <!--Document Created using EDGARizerAgent 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Washington, D.C. 20549</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">FORM 8-K</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">CURRENT REPORT</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date of Report (Date of earliest event reported): May 3, 2012</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 16pt; FONT-WEIGHT: bold">AETHLON MEDICAL, INC.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Exact name of registrant as specified in its charter)</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="33%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Nevada</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(State or other jurisdiction </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">of incorporation)</font></div>
</td>
<td valign="top" width="33%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">000-21846</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Commission File Number)</font></div>
</td>
<td valign="top" width="33%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13-3632859</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(IRS Employer </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Identification Number)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;&#160;&#160; <br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8910 University Center Lane, Suite 660</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">San Diego, California</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Address of principal executive offices)</font></div>
</td>
<td valign="top" width="50%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">92122</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Zip Code)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;&#160; <br>
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Registrant&#8217;s telephone number, including area code: (858) 459-7800</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Not applicable</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Former name or former address, if changed since last report.)</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="96%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="3%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="96%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="96%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="3%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="96%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="96%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="3%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="96%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="96%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="3%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="96%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div>
</td>
</tr></table>
</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">&#160;</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;&#160;&#160; </div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">FORWARD LOOKING STATEMENTS</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This Form 8-K and other reports filed by Registrant from time to time with the Securities and Exchange Commission (collectively the "Filings") contain or may contain forward looking statements and information that are based upon beliefs of, and information currently available to, Registrant's management as well as estimates and assumptions made by Registrant's management. When used in the Filings the words "anticipate, "believe", "estimate", "expect", "future", "intend", "plan" or the negative of these terms and similar expressions as they relate to Registrant or Registrant's management identify forward looking statements. Such statements reflect the current view of Registrant with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to Registrant's industry, Registrant's operations and results of operations and any businesses that may be acquired by Registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.</font></div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Although Registrant believes that the expectations reflected in the forward looking statements are reasonable, Registrant cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, Registrant does not intend to update any of the forward-looking statements to conform these statements to actual results.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 7.01&#160;&#160; Regulation FD Disclosure.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On May 3, 2012, the Company issued the press release attached hereto as Exhibit 99.1. &#160;</font></div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Limitation on Incorporation by Reference</font></div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 9.01&#160;&#160; Financial Statements and Exhibits</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit No.:</font></div>
</td>
<td align="left" valign="top" width="90%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Description:</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="90%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="10%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99.1</font></div>
</td>
<td align="left" valign="top" width="90%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Press release issued May 3, 2012</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;&#160; <br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">SIGNATURES</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="36%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">AETHLON MEDICAL, INC.</font></div>
</td>
</tr><tr>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></td>
<td align="left" valign="top" width="36%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">/s/ James A. Joyce</font></font></div>
</td>
</tr><tr>
<td align="left" colspan="3" valign="bottom" width="36%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dated: May 3, 2012</font></div>
</td>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="36%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font>
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">James A. Joyce</font></font></div>

<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chief Executive Officer</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3</font>

<div>
<hr style="COLOR: black" align="center" noshade size="1" width="100%">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>aethlon_8k-ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
<head>
    <title>aethlon_8k-ex9901.htm</title>
    <!--Licensed to: Publicease, Inc.-->
    <!--Document Created using EDGARizerAgent 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<div>
<hr style="COLOR: black" align="center" noshade size="1" width="100%">
</div>

<font style="FONT-WEIGHT: bold"> EXHIBIT 99.1</font></div>

<div>&#160;</div>

<div><img src="logo.jpg" alt=""></div>

<div>&#160;&#160;&#160; </div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Aethlon Medical Note:&#160;&#160;Fiscal Year Revenue Guidance</font></div>

<div>
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160; <br>
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">SAN DIEGO &#8211; May 3, 2012 &#8211; Aethlon Medical, Inc.</font> (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.</font></div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On May 19<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> of last year, we introduced and began marketing the Aethlon ADAPT&#8482; system, a technology platform that converges the capabilities of <font style="DISPLAY: inline; COLOR: #131313">plasma membrane technology and affinity drug mechanisms.&#160;&#160;Our Aethlon ADAPT&#8482; system provides a foundation to create a pipeline of device-based therapies that selectively target disease-enhancing particles from the entire circulatory system.&#160;&#160;</font>On October 3<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">rd</font>, 2011, we disclosed our first success in marketing the Aethlon ADAPT&#8482; system, a $6.8 million multi-year contract from the Defense Advanced Projects Agency (DARPA) that has since transitioned us from a development-stage to revenue stage organization.&#160; Under this contract, our tasks include the development of a dialysis-like device to prevent sepsis, a fatal bloodstream infection that is often the cause of death in combat-injured soldiers.&#160;&#160;As a courtesy to shareholders and other interested parties, the purpose of this note is to provide revenue guidance for our March 31, 2012 fiscal year end.&#160;&#160;As a result of achieving five contract milestones between October 1, 2011 and March 31, 2012, we expect to recognize approximately $1,350,000 in contract revenue.&#160;&#160;We also recorded our first sale of research diagnostic tools during the fiscal year, which will have a minimal effect on revenue reporting.</font></div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Aethlon Medical</font></div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT&#8482; System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT&#8482; product pipeline includes the Aethlon Hemopurifier&#174; to address infectious disease and cancer; HER2osome&#8482; to target HER2+ breast cancer, and a medical device being developed under a contract with DARPA that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit </font><font style="DISPLAY: inline; COLOR: #0000ff; TEXT-DECORATION: underline">www.aethlonmedical.com</font><font style="DISPLAY: inline">.</font></font></div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">All financial disclosures, anticipated revenue recognition amounts and other information related to the financial results and operations of the Company set forth above are unaudited and are subject to year-end audit adjustments and footnote disclosures. The Company has not completed its fiscal year audit and the revenue guidance provided herein should be regarded as preliminary.&#160;&#160;</font>The foregoing fiscal year-end revenue guidance should not be construed as a projection of future revenue activities during any period of fiscal year 2013. Future revenue of the Company, if any, may differ materially from that set forth above.</font></div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies of the Aethlon ADPAT&#8482; system or the Aethlon Hemopurifier&#174; as an adjunct therapy to improve patient responsiveness to established cancer therapies, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; COLOR: #464646">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">#&#160;&#160;&#160;#&#160;&#160;&#160;#</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Contacts:</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">James A. Joyce</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Chairman and CEO</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">858.459.7800 x301</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font color="blue" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font color="blue" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">jj@aethlonmedical.com</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Jim Frakes</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Chief Financial Officer</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">858.459.7800 x300</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; COLOR: #0000ff; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">jfrakes@aethlonmedical.com</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Marc Robins</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">877.276.2467</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; COLOR: #0000ff; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">mr@aethlonmedical.com</font></font></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!4`,0#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H)P*H^(O$=CX2T6[U/5+VUT[
M3K&)IKFZN9%CA@11DLS'@`#N:_,;]M;_`(.$HM%U*\\/?!33+74VA9HI/$NJ
MQ,;=CTS;09!<>CR8!_NFO?X?X8S+.JWL,OIN5MWM&/J]E^?D>5FN=8/+J?/B
MIVOLMV_1'ZBESMR!FHQ>*S[05+'MN&:_FU^+G[</Q@^.M]+-XG^(_BR^24D_
M9X;][2V3V6*(J@'X5YS%XIU:"Y$T>KZM',#N$BWLH<'USNSFOUO#>`^+E3OB
M,7&,NR@Y+[VX_D?#5O$JDI6I4&UYR2_"S_,_J4$A],4X'(S7\XGP4_X**?&W
M]GZ\A?PY\1O$9MH2#]AU*X.HVCCT,<Q;CZ$5^DO["W_!>[P]\8M3LO#'Q6L;
M+P7KUR5AM]8@8_V3=N>`)-Q+6[$^I*<_>%?+<0^$F=973=>E:O!;N%[KUB]?
MNN>SE7'67XN:I5;TY/OM]_\`FD?HM14-K=I>1+)&ZO&X!5E.0P/0@]Q4U?EJ
M=S[4****8!1110`44A8"CS`>]%P%HJ&^U&WTNQFNKF>*VMK:-I9997")$BC+
M,S'@``$DGH!7._"7XV>#_CWX8DUOP1XHT'Q=HT5S)9M?Z/?1WMKYT>-\8DC)
M4E<C.#QF@#J**^2?@Y_P5P\,?&/_`(*F_$']E:U\)^(+/Q-\/=*.K76MS30F
MPND"6C;44'S`?]+3J/X&]J^MJ`"BL3XF>-X?AG\./$'B2X@EN8/#^FW.I2PQ
MD!Y5AB:0JI/&2%P,^M>#_P#!*W_@I3H'_!5;]F%_BCX:\-ZSX6TQ=8N='^QZ
MG+%).9(5C9GS&2NT^8,=^#0!])T444`%%%%`!4=S)Y49;.`HSR<"I*^4/^"R
MW[3EQ^S-^Q3K<NF7!MM>\7R+X?T^1#AX?.5C-(OH5A5\'L2M>AE66ULPQE+`
MT/BJ245\^OHMWY')CL9#"8>>)J;03?W'YW_\%BO^"FE[^U#\1+_X>^$-0EA^
M''A^X,%P\+X7Q!<HV&D8]X4881>A(W'JN/AKI3<K$GH%%?KI_P`$E_\`@D9X
M(UG]GNU\<?%CPK:^(]9\7J+K3K#4`WDZ;9$#RFV`C]Y(/G)/12HXYS_7N-Q^
M4<$9-3@HMQO9)6YIRZR=^O5OIHET1^#8;#8[B',)-O5J[;VBNB_R/R-SBC(K
M^B$_\$J?V=C_`,TB\'_^`S?_`!5?.W_!3OX;?L<?\$T_V7+[X@^/_A-HTNGS
MW<6DV=CH\6S4[^YE)PMOND4!E17D)R,+&?8'Y->.N4W_`-WJ?^2__)'T#\-\
M=;2K#\?\C\9Z"-RD'D'@CUKO?VA_AAH_P\\7V-]X2U.37OA]XRTZ'Q%X1U9U
MPVH:;.,IO':6-@\4B]0\;`UP5?L&`QU#'X:GB\-*\)I-/R?]69\#B,/4H594
M:JM*+LUYGZ;_`/!$+_@IM>Z1XFTWX+>/=2DN-.OF\KPMJ%Q)EK24#(LG8]4;
M'[O/0_+T*X_6Q6#C(K^6+3]2N=&O[>\LYY;6\M)5G@FB;:\,BD,KJ>Q!`(^E
M?T>_L%_M%#]JG]D_P7XUD9#?ZG8"+457HEW$3'-],NI(]F%?S5XQ\(TL!B89
MKA(VA5;4DME/>_\`V\K_`#3?4_7.`<]J8BG+`UW>4%>+_N]OEI\F>PT445^)
MGZ,>!?MZ)^T9J?A3P[IG[.4_PYTO7=0U%DUO6/&*336VE60C)#PPQ?-)*7V@
M`@J`#FOC[]J'P=_P44_9/_9_\5?%&']H_P"#7C8>#-*GUS4/#MYX"BTRUE@M
MT,LJ17(?>6V*V-Q3)XR"16__`,%0O^"N/Q4^&W[<'A#]E/\`9M\$:#XF^,WB
M_3AJMQJWB.1TTK0;9A(V\HI!D*QQ/(S$X4;0%=FP//?VO?\`@DC\;?C5^R1\
M1_$G[37[4_C+QU#H?AG4M97P9X.L8O#WAMY[>TDEB2;8OF7,8=0<.JDXH$>P
M?LZ_\%P=.^*?_!(WPQ^T7KWAI;3Q)K]Q+HD?AZTF)CO=5BFDA*Q,<L(3Y9DY
MR57(Y.,]MX+\&?MF_$;P8GB:\^('PQ\$:G?1"ZMO"I\,M=Q6P896&>X+[PW8
ME0<5^1_['^ERW/\`P0Y_99OKJ[O-.\.VOQ'UJ+4;VV(#V9>\RDJY!`9524@G
MC(K]CK?_`()T^(KV%)(?VG?V@)(G4,CKK5J58$9!!\CIBOT#!X?!X+)L/BI2
M@JE:4[N=/VFD6DHQ5FEW;^+5:V/D<15Q6(S"K0BI.--1LHSY/B5[O5-]ETT/
MGKXN_MH?'C]L3]A[XM^$_`\/P_\``7QF^&CW=EXYM=?CFN-.N])%I=+<-9A`
MS+,S(`N[*C!.<,*^/_\`@VH\(_MG:K^PYX4O/A'XL^!^F?!I/%UU]OL/$-C=
MR:VZB>/[7L>-#'EDSLR>#UQ7Z3VW_!._0OV1/A)\?/&%IXO\7^+M?\:^#M23
M4KG7)H99)66UF;S,HBDL2>2<]*\(_P"#0M@O_!&_2,G&?%FK_P#HR.OE\]E@
M)8V4\M_A.S2U5G9<R5];<U[7Z'N91'%K"QCC?C5^M]+Z7MI>UK^9\/\`C+]J
M7QI^RW_P=/?M"R_#/P(_Q&^)GC;28?#'A?1VF\BT^US6FES&XNI,C9;Q0P2R
M.<CA<949(^K_`-HF7_@K#^SO\(-4^)__``G?P!\7PZ!:2:KJ7@_1]%8R)!&I
MDD6)Y(4>4J@;($P8@';N.*X+]BK1+34_^#Q?]HRYN+>.:?3O"+SVKL,F!S:Z
M1&67W*.Z_1C7[#?'(_\`%E/&(]-#O?\`TG>O'/3/D']AS_@I'%_P50_X(\>+
M_BC)H\7A_6_[`UO2-;TZ&0R06][!:/O,1/S>6ZNCJ&Y&_!)QD_/O_!I-XXTK
MX9_\$4-:\1:[>PZ;HN@^+-;U"_NY3B.U@BM[>221CZ*JDGZ5YY_P:^_\H#_C
MA_V%O$?_`*:;>O,/^"5&@:QXG_X-%/VB+/0HYY=1>3Q'($ASO>)(+5Y@,=<Q
M+)QW'%`CZ*^!'[?W[:W_``65U[Q!XL_9N;X>?`[X$Z3J$VF:3XC\6::VI:KX
MA>,X:1(2KH!R,@*%0DKO=E.+5Q_P5-_:@_X)4?M0>"/!/[9%IX$\9?"_XEWZ
MZ7I'Q)\)VSV2Z9<D@8NH2JJ`-P9EV*0NYE9PC+7O'_!M+XJ\/>(?^"+/P770
M9(-NFVEY9:@B,"T5ZM[.TP;T)+!L'LZUX/\`\'CFN:.O_!+[PYH\[0R^(M:\
M>Z>NB6X7=/)(D%R9#&.O"-@D?WU'<4`=Q_P<!?\`!7GQY_P2J\8?L_7?AA]'
M?PKXTUFY7Q6+C3_MES+8V[VC.+8[U"R&.67!.1DKZ5AP:U_P4^_:]\,'XA>#
M]6^"'P%\.:M&+W0?"&N6CZAK!M6`:(7LS02JDK(02!MP3@JIS7S_`/\`!P]X
M$NM8\6?\$W_#/BY/M=[<Z_9Z;K2N/]?(6TB.<$>YW_G7[E)&$!`'&:!GYF_\
M$4O^"O7Q:_:5_:?^*'[-W[1_AG1/#_QF^%\371NM*3RK?5($D2.3,>YEW#S8
M75XSL=),[5QSRO\`P<K>+YGUWX5>'PQ^S)#?ZBRYX+EHHU/X#=^9KS?]CWG_
M`(/'/VBO^Q(_]M-&KTC_`(.5O!]PNO?"C7UC9K:2&_TUB!GY\Q2*/J03CZ&O
MT+PLY/\`6;#\_P#>MZ\DCY/C?F_L:KR^5_2Z/D'_`()A?L;R_MH?M4Z1HEU`
M[^%=#*ZKX@EP0OV9&&V'/K*^$^FX]J_H5L;&+3[2*&"*.&&)%1$085%`P`!V
M`%?*_P#P2$_8L_X9$_96L&U2U\GQAXS":OK19?GM\K^YMB?^F:'D?WW>OJX_
M*OTI^)G%/]M9O+V;O2I7C#L^\OF]O)(G@[(_[/P*=1>_/67EV7R6_F#OL7."
M?I7\G7_!T)_P4\_X;L_;QN/!WAG43<?#KX//-HVGM%)NAU'42V+R[&#@C<JQ
M*?[L.1]\U_03_P`%I_VO;S]EW]B3Q+:>'=3&F>/O'-K/H?AR9#B2TEDC(DNA
MZ>4C9![,R5_&AK^DW>AZS=6E\DD=Y;S/'.LARP<'!S[YKXJIEN)AA88V<&J<
MVU&71N-K_=?\^S/I:>+HSK2P\97G&S:[7V/TC_X)&_&1OVH?V8_$G[/^JS-/
MXO\``@NO&7PY+G+W=OC?JVDIZY11=QK_`'HYL?>KI0VX`CH:_-KX!_'#Q%^S
M7\9_#'CWPE?OIOB/PCJ,.J:?.IX66-MP##NC#*LO1E9@>#7ZU_'Z/PY\0;+P
MO\6O`<"V_@#XNV!UO3[9#E=%O0VS4-,)[&WN-X`[QM&>AK]X\%>*OCR.O+O*
MG_[='_VY?]O'YAXA9):4<RI+>T9?H_T^X\YK]FO^#<KQA-K'[)GBS1Y2QCT3
MQ-(T.>BK-!$Y`_X$K'_@5?C+7[-?\&Y7A";2/V3/%FL2*RQZUXFD6'/1EA@B
M4D?\"9A^%?:>,OL_]7)<^_/"WK?_`"N>#P%S?VQ'EVY97^[_`#/T*HHHK^13
M]V/S^_X*3_\`!&WQ=^T=^V5X*_:3^!GQ0B^$_P`;/!EF-+:XOM/^WZ9K%H/,
M`25`<J=DLD;?*X="!@%0U=+\/?V5OVPOB;X=\<^'?CC\9/A-JGA7Q1X.U/P]
M;6'A3PM+;.M[=0^3'=S2RMN*1JTA\M"NXL.@%?;E%`,^(OV&?^"->B_LW_\`
M!+NV_9J\?:W;^.K&.\O+U]5L[0V+1237#31R1*S.4>,MP<G/.1@D5'X&_8M_
M:L^`6@1>&/`GQ_\`">H>$[!1%IP\3>&S=7UG$.%CWJ3N"C`&3@8X`K[A(!["
MDV@]A7KX#/<7A*+PT.65-N_+.,9I.UKI23L[=5:_4\W%950KU%6=XS2M>,G%
MV[-IJZ/#_@;^SKX[LOA!XN\/?%SX@O\`$74?&2S6UQ<6UDNG06-K+!Y+001K
MP.KMNZDL/2OSW_8>_P""%_[7O_!.O5G\'?"_]JCPWI_P8N/$2ZM<Z9<>'!-J
M$L'F)YJH9(W$,LD2!6:.0`GYL"OUYP,YQS39&P*\[$XB5:I*M-)-]DHKY)))
M>B1VT*,:4%3C>R[MM_-O5GQ!\!/^"1&I_!K_`(+/?%+]JV;QQ8W^G_$31#I,
M?AQ-,:.:Q.RQ7>9_,(<?Z(>`@^_UXY^R?B!X9?QGX%UK1XYEMWU:PGLQ*R[A
M&9(V0-COC=G'M7Q%\0?^"AOC3X,?M(?&;2->N;2[\-6=O<6/@>!;54D_M:"W
MLG%JS#F0RF]0@'LC5R.D_MF_&[5_`OP7T^\\3:DGB3Q3JWB?3=>N?#OA>VU*
MZN&TZ4)'Y-L^%`&&W$8XYYQ7T]+@S'SIQJ\T5&233;>ON.H]D]E%I_WK+S/#
MEQ+A%-T[-M;K3^9177K>Z\M3O?\`@E1_P2"U3_@G%_P3V\>?!&^\<V/BN[\9
M7>IW4>K0::UI':_:[..W`,1D8MM*;L[AG..*Z?\`X(V?\$O[K_@ES^Q5<?"'
M7/$^G>/$N]:O=4FNXM.-K#+'<)$AA:)W?(Q&<Y."&Z57U/QG\6_%?[1'P]^'
M.F?$O5?#9U7P)=>)-1U"]\*67]H7-S'>1QHLMNV4A(24`JIZH/4URG@#]O;X
MA77C?P#HVL7NEZBUEXI\4^'/$%SIUFJP^(TTNS$T,T()/E,Q(#!"1N4CIQ7)
M#AK$U(\U*<9:.5KN]ESM/6*6O([*][VO8UGGE",N6<9+5*^EK^[V;VYD>3:7
M_P`$*_C;^PO\8/$FN?L:?M`V?PT\%^+KQM0OO`OBK1QJND6DS=X&PQ50,*/E
M#A0`78**V_@I_P`$*O'_`,7OVM/#7QM_:]^-*_&_Q)X%F%QX8\-Z;I:Z=X>T
MF97#I(8L`/AU5MH1=S*NXN%`KZ-_8M\9?$;XV_"WPW\9/%?Q+LK7PYKMM-JL
MOAFRT>V2PL;4APD3739F+Q@!G?(^92,`5Y#^S-_P4T\3?%7]I&[M=6NVA\&>
M/;75&\'6TVB36G]GR6F6@S<N@2Y-S`LDN%9MI`'>ICPUBYRKPI-2='XK7W5[
MI::M)-WVLM'LG4L]H15)S37M/AVVTLW9O1W2[WZ;G5_\%4?^"3^J?\%&/C=^
MSWXNL?&EEX5C^"/B;_A()[:XTYKMM67S[27RE8.OEG_1B-Q#??Z<5]K5XM_P
M3[^+GB#X\_L=>`_&'BBYCO=>UZP,]Y-'"L*2.)77(1>%X4<"JO\`P4-^-/B'
MX`_LPZCXG\+7D-EK-OJ6G6T<LL"S*$FO(HI!M;CE'8>V<UP1RRL\?_9RMS\_
M)Y7O;[OD=KQ])87ZX[\O+S>=K7/#_@O_`,$B-4^%'_!:CXE?M8R>.+&]T[Q[
MH?\`8\7AQ=-9)K,^391^89S(58?Z(3@(/O\`7CGZ=_:%_9C\+_M,#PFGBBT^
MV0^$-=@\06B<;7GB5@J/GJAW9([[17ROJ/[>_C_X8?M-?%2S\57.GM\,[?5K
MCPQX?U(6RQG0-6CL([J".X8#YXY_,*JS='0#C-:/P<_:'^*G[5GCOPGX+TWQ
MG:^!WM/AUI7B[7-5ATF"[OM8NKW(V01R_NXX4VDL0I.Y@O%>S#AS,,-;$QJ1
M@E%2Y[O1->2;OK9I*^O\NIY4\[PE>]!P<FVURV6K3\W:SW3;Z'VW']W\:9>S
MI:V<LLKI%'$A=W=MJH`,DD]@*I>#]-OM%\*Z?::GJ1UC4;:!(KF^,"P&\D`P
MTAC7Y4+')VC@9XKXG_X+F?MIG]GC]G$>"=#O##XK^(B26A,;X>ST\<3R^Q?(
MC'^\Y[5Y>29/6S3,*67X;64W:_9=9>B6IZ>99A3P6%GBJNBBK_/HOF]#\T_^
M"I?[9,G[9O[5NK:K97#R>%/#N[2-`3/RM`C?//CUE<%L_P!W8.U?EM_P4&^"
MPTC7K;QE8PXMM2(M]0"CA)@/E?\`X$HP?=?>OKI5VJ!Z5C_$'P/9?$CP7J.A
MZ@@:UU&$Q$XYC;^%Q[JV#^%?U[GW!&&Q?#W]BT%;DBN1]I16C_[>N[_XF?A.
M4\15L-FO]HUG?F?O?X7T^73T/S%;[W'%?H9_P10^.4?Q5T/Q1^S%K]Y&B>-9
M3XA^'\T[;5L?$D,6TVH8_=2^MU,)'>6.#O7R%JG['OQ$L-2G@C\+W]VD,C(L
MT6TI*`2`R\]#U_&K/A;]G7XK^!/$NGZWI/AW7--U72+F.]LKN!E22UGB</'(
MK;N&5E!!]17\K8')L^R_%PQ5##5%.G)-/DGNGZ:K\T?M>+QN68K#RH5:T'&2
MM\4>OSW/T$M]%O;S6(]-AL[B34I9Q:):A#YK3%M@CV]=V[C'K7]'7[!7[.P_
M95_9.\%^"9`G]H:98"7467H]W*3+-^`=R![**^+/^"5W[$D7[3'C'PA^U1XY
M\.W?A;6M?TN'4I_"MY9&`0:\-T5SJ"`\&WE*BXA`[SD_PBOTS5=HK[+Q-X\I
MYW3P^#PR:C%*4TU;WVK<NO\`+K\VSYO@SAF>7SJ8BN[MZ1_PWWT[Z?<+1117
MY&??!1110`4444`%-<$XP*=10!Y;XH_8U^'7C7Q)#J^J^&K>]U"#Q)'XMCED
MFD.S4DACA6<#=C_5Q1C;]T[0<9K&\2?\$_/A?XGTW1K:?1-0MU\/7M_J.GR6
M6KW5I-;3WTGF73+)'(K_`+QN2,X'08%>UT5VT\SQD+<E:2MM:3TTM^3:^9R2
MP&&E>]-:[Z>G^2^X\/\`%7_!/KX:^-'T1]1T_7Y;GPYITFE65VGB*_CNQ:R2
M>8\3S+*'D4OR=Y/0#H*Z'P[^Q]\._!__``A0TGPQ9Z:GP\:YDT%+=W1+-KA"
MD[$9_>,X)R7W$DYZUZ?11/,\;."IRK2:5].9]4T^O6[^]]Q1R_#1DY1IJ[MT
M73_AE]QX--_P3<^%$D^J^1HNKZ;8ZT+C[9I=AKU]:Z;(9U996%JDHB4L&;.U
M1UKMO&7[+G@CQYX,\+:!J.AQMI?@FYM[O0X89GA.G201F.(HR$'`0E2,X(/.
M:]#HHJ9EBYM2G5DVMM7Z=^V@XX##1348)7\EZ_F?/%I_P38\">#_``A+H_@Z
M^\9>#H)T2W)T_P`1WKK#;^<DDD44<DI2/>$*%U`90[8()KUOXL?!/PY\;_`$
MGAGQ+8'4=%EE@F:W,SIEX9%DC.Y2&X=%/7G'.:ZRBIK9ABJLU5J5&Y)W3;UO
MIK??H%+`8>G%PIP235FNENUMCS+Q1^R%\/O&OA/QQH>K>'8+_2_B->?VAX@M
MY97*WMP$C02`YRC`11X*8P5!ZUD>,?V#/AEXTT?PS:3:%=V,W@^P72](O]-U
M2YL+^SM%``@%Q#(LC1X`^5F(SSUKV2BJAF6,A;DJR5G?XGO9+OV27HK;!/`8
M:::E33OY+O?\]?4XOP-\"/#WPZ\11ZKIEO?K?1:3!HBO/J,]P#:PL60%9'8%
M\DDR$;V[DU\0_P#!5+_@CKXL_:W^)ES\1?!?BN.ZUQ[6.V;0M8?R[=8XQA5M
MIE'[O))8JXP68G<,U^B5(PR"*[LEXBQV58Q8_"3_`'B5M5>Z[._3[GYG+F.3
M87&X?ZM6C[M[Z:6?<_FO^+G[#_Q?^!5[)#XH^''BRP6,D?:(;![NV?W$L6Y"
M/QKSJ+PMJL]R(4TK57F)VB-;.4N3Z8VYS7]2:Q;0`#TIHM$$FX)&&]=@S7Z]
MAO'?%QIVK82,I=U)I?<U+\SX:MX:T7*]*NTO.*?ZH_G*^"?_``3I^-O[05[#
M'X<^'/B);68@?;M2MSIUH@]3)-MR/H":_23]A3_@@CX>^#FJV7B?XKWEEXTU
MZV99K?1[=3_9-HXY!?=AIV![,`G'0U^B?D@G).:<HVC'I7RW$7BUG6:4W0IV
MHP>ZC?F:[.3UMY*Q[.4\"9?@ZBK5+U)+^;;[O\[D=M:K:Q+'&JI&@`55``4#
MH`.PJ6BBOR\^T2"BBB@84444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
8%`!1110`4444`%%%%`!1110`4444`?_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
